Boehringer Ingelheim is investing more than €100m ($126m) at its Dortmund, Germany site to expand production capacity for its Respimat inhaler, which is the third time in the past four years that the company has made a capacity-expanding investment at...
Hovione has obtained a US patent for a cheap capsule-based dry powder inhaler that it claims is cheaper for manufacturers to produce and easier for patients to use.
Novartis has confirmed it is closing a UK facility as part of a global R&D review but remains silent on rumours specific business units will be divested.
The licensing and potential purchase of the Taper Dry Powder Inhaler (DPI) technology from 3M complements Adamis’ portfolio and future formulation expansion, Adamis says.
Dry powder inhaler firms may soon be able to eliminate lactose from formulations if a new high dispersibility particle production platform is successful in trials.
Aptar Pharma says its new eDevices can help companies gain quicker regulatory approval for their nasal drug products without having to re-do clinical trials.
A novel spring-powered inhaler system to deliver the blockbuster
COPD (chronic obstructive pulmonary disease) treatment Spiriva
(tiotropium) has successfully completed the EU approval process,
paving the way for its introduction into...
A drug discovery collaboration between Ranbaxy and GlaxoSmithKline
(GSK) is bearing fruit with the companies stepping up their
respiratory inflammation research.
India's Ranbaxy Laboratories has stepped up its efforts to dominate
the domestic novel drug delivery system (NDDS) market, in-licensing
two new drugs from Europe in as many weeks.
On your marks, get set go! The FDA has fired the starting gun and
Pfizer is finally off and running after the long-awaited approval
of Exubera - the world's first non-injectable insulin - expected to
hit the US market by mid-year...
Merck & Co said it would cut an additional $1 billion (€832
million) through 2010 as it struggles to regain R&D momentum
after mounting lawsuits, generic competition and falling revenue
and profit threaten to engulf the company,...
Chemicals and pharmaceuticals firm Merck KGaA saw turnover rise but
pretax earnings dip in the second quarter of 2005, although the
results were skewed by the gain from its divestment of its
laboratory distribution business VWR International.
Novartis has acquired a global license to a combination drug and
inhaler device for chronic obstructive pulmonary disease (COPD) in
one of the largest deals signed by the UK biotechnology sector,
reports Phil Taylor.
Germany's Boehringer Ingelheim is claiming the number two spot
among the top 20 pharmaceutical companies for 2004 growth,
reporting double-digit gains for both revenues and operating
profit.
Shares in German group Altana advanced at the end of last week on
the re-emergence of rumours that it is planning to separate its
pharmaceuticals and chemicals businesses via a spin-out.
The Food and Drug Administration (FDA) has set the end of 2008 as
its deadline for the complete phase-out of albuterol inhalers using
ozone-depleting chlorofluorocarbons (CFCs) as propellants,
reports Phil Taylor.
A compound targetting respiratory syncytial virus - a major threat
to immunocompromised patients - has completed Phase I trials,
raising hopes of the first effective treatment for the virus,
writes Wai Lang Chu.
Germany's Altana has filed for European marketing approval of the
first drug in new class - the phosphodiesterase-4 inhibitors - for
asthma and chronic obstructive pulmonary disease.
A new drug for asthma and chronic obstructive pulmonary disease
(COPD), developed by Swiss drugmaker Novartis, will make use of two
technologies developed by UK drug delivery firm SkyePharma.
Meridica has licensed its newly-designed Xcelovair dry powder
inhaler (DPI) to Pfizer in what amounts to something of a coup for
the small UK start-up.
